Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2009

View Archived Issues

Veltuzumab active at low doses in recurrent non-Hodgkin's lymphoma

Abeta1-15 vaccine ACI-24 shows positive safety profile in a mouse model of AD

Optimized formulation of Pronucleon peptides developed as an in vitro diagnostic tool for AD

Oral formulations of TBR-652 evaluated in healthy volunteers

ABT-089 reverses scopolamine-induced cognitive deficits in healthy volunteers

Novartis reports first results for the first half of 2009

YM-254890 shows potent bronchodilator activity in rodent models

Bristol-Myers acquires Medarex, thereby gaining rights to ipilimumab

Merck submits MAA for cladribine tablets for multiple sclerosis in Europe

Nabriva initiates phase I trial for pleuromutilin antibiotic, BC-3781

PharmaMar commences phase II Zalypsis trial in endometrial and cervical cancer

Schering-Plough files NDA for mometasone/formoterol combination for asthma

Taiho receives approval for TS-1 in Singapore

Theravance patents muscarinic receptor antagonists for the treatment of COPD and asthma

Novel PI3K inhibitors claimed by UCB for the treatment of cancer

Janssen discovers novel CB2 receptor agonists for the treatment of pain

Alcon and AstraZeneca collaborate on ophthalmic drug discovery

Takeda provides update on fixed-dose combination of alogliptin and Actos

GlaxoSmithKline completes acquisition of Stiefel

Regeneron enrolls first patient in phase III VEGF Trap-Eye program in CRVO

GSK and Enigma sign commercial partnership to develop influenza diagnostics

Peplin initiates final phase III PEP-005 gel trial in actinic keratoses

Kyowa Hakko Kirin reports results from phase III trial KW-2246 trial

AcelRx reports results from phase II study of ARX-01 Sufentanil NanoTab PCA system

Galapagos receives milestone payment under osteoporosis collaboration with Lilly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026